Annual report pursuant to Section 13 and 15(d)

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY

v3.24.1
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)
Total
Prefunded Warrants
Common Stock
Common Stock
Prefunded Warrants
Additional Paid-In Capital
Additional Paid-In Capital
Prefunded Warrants
Accumulated Deficit
Balance (in shares) at Dec. 31, 2021     1,904,434        
Balance at Dec. 31, 2021 $ 5,864,166   $ 1,904   $ 53,118,425   $ (47,256,163)
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Stock-based compensation expense (in shares)     5,935        
Stock-based compensation expense 629,032   $ 6   629,026    
Warrant exercises (in shares)   78,667 78,667        
Warrant exercises 1,967   $ 79   1,888    
Common stock issued in acquisition (in shares)     1,665,083        
Common stock issued in acquisition 9,858,155   $ 1,665   9,856,490    
Finance charge from Sciences warrant modification 120,228       120,228    
Net loss for the year ended (19,481,602)           (19,481,602)
Balance (in shares) at Dec. 31, 2022     3,654,119        
Balance at Dec. 31, 2022 (3,008,054)   $ 3,654   63,726,057   (66,737,765)
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Stock-based compensation expense (in shares)     10,333        
Stock-based compensation expense 987,510   $ 10   987,500    
Warrant exercises (in shares)       66,566      
Warrant exercises   $ 282,906   $ 67   $ 282,839  
Conversion of multi-draw credit agreement - related party and accrued interest (in shares)     165,517        
Conversion of multi-draw credit agreement - related party and accrued interest 2,980,521   $ 166   2,980,355    
Common stock issued in acquisition (in shares)     5,436,378        
Common stock issued in acquisition 21,609,586   $ 5,436   21,604,150    
PIPE Financing, net of equity issuance costs (in shares)     2,989,981        
PIPE Financing, net of equity issuance costs $265,053 11,734,947   $ 2,990   11,731,957    
Warrants issued with Convertible Note 925,550       925,550    
Common stock issued for fractional share adjustment in reverse stock split (in shares)     26,349        
Common stock issued for fractional share adjustment in reverse stock split 0   $ 26   (26)    
Net loss for the year ended (37,644,784)           (37,644,784)
Balance (in shares) at Dec. 31, 2023     12,349,243        
Balance at Dec. 31, 2023 $ (2,131,818)   $ 12,349   $ 102,238,382   $ (104,382,549)